25 XP   0   0   10

Cytodyn Inc
Buy, Hold or Sell?

Let's analyse Cytodyn together

PenkeI guess you are interested in Cytodyn Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cytodyn Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cytodyn Inc

I send you an email if I find something interesting about Cytodyn Inc.

Quick analysis of Cytodyn (30 sec.)










What can you expect buying and holding a share of Cytodyn? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$-0.12
Expected worth in 1 year
$-0.13
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$-0.01
Return On Investment
-8.5%

For what price can you sell your share?

Current Price per Share
$0.15
Expected price per share
$0.13 - $0.16
How sure are you?
50%

1. Valuation of Cytodyn (5 min.)




Live pricePrice per Share (EOD)

$0.15

Intrinsic Value Per Share

$0.63 - $0.79

Total Value Per Share

$0.51 - $0.67

2. Growth of Cytodyn (5 min.)




Is Cytodyn growing?

Current yearPrevious yearGrowGrow %
How rich?-$119.3m-$102.9m-$12.1m-10.5%

How much money is Cytodyn making?

Current yearPrevious yearGrowGrow %
Making money-$12.9m-$43m$30.1m233.0%
Net Profit Margin0.0%-891.3%--

How much money comes from the company's main activities?

3. Financial Health of Cytodyn (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#994 / 1010

Most Revenue
#1002 / 1010

Most Profit
#604 / 1010

Most Efficient
#441 / 1010

What can you expect buying and holding a share of Cytodyn? (5 min.)

Welcome investor! Cytodyn's management wants to use your money to grow the business. In return you get a share of Cytodyn.

What can you expect buying and holding a share of Cytodyn?

First you should know what it really means to hold a share of Cytodyn. And how you can make/lose money.

Speculation

The Price per Share of Cytodyn is $0.146. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cytodyn.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cytodyn, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.12. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cytodyn.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.01-8.2%-0.01-9.0%-0.04-29.7%-0.03-21.3%-0.02-13.2%
Usd Book Value Change Per Share-0.01-3.4%0.00-2.1%-0.02-14.6%-0.01-3.9%0.00-2.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-3.4%0.00-2.1%-0.02-14.6%-0.01-3.9%0.00-2.2%
Usd Price Per Share0.26-0.23-0.38-1.15-0.96-
Price to Earnings Ratio-5.42--4.43--4.01--8.84--17.24-
Price-to-Total Gains Ratio-51.64--29.06-1,505.24-329.07-523.33-
Price to Book Ratio-2.16--1.95--3.72--65.85--44.64-
Price-to-Total Gains Ratio-51.64--29.06-1,505.24-329.07-523.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.146
Number of shares6849
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.00-0.01
Usd Total Gains Per Share0.00-0.01
Gains per Quarter (6849 shares)-21.33-38.75
Gains per Year (6849 shares)-85.30-155.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-85-951-156-165
20-171-1802-312-320
30-256-2653-468-475
40-341-3504-624-630
50-427-4355-780-785
60-512-5206-936-940
70-597-6057-1092-1095
80-682-6908-1248-1250
90-768-7759-1404-1405
100-853-86010-1560-1560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.037.03.00.0%0.043.016.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%15.025.00.037.5%20.039.00.033.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%3.00.017.015.0%3.00.037.07.5%4.00.055.06.8%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%15.025.00.037.5%20.039.00.033.9%

Fundamentals of Cytodyn

About Cytodyn Inc

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Fundamental data was last updated by Penke on 2024-04-21 01:53:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Cytodyn Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cytodyn earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cytodyn to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cytodyn Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-891.3%+891.3%
TTM-5Y314.8%-314.8%
5Y314.8%10Y157.4%+157.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY-891.3%-282.3%-609.0%
5Y314.8%-436.8%+751.6%
10Y157.4%-597.3%+754.7%
1.1.2. Return on Assets

Shows how efficient Cytodyn is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cytodyn to the Biotechnology industry mean.
  • -116.1% Return on Assets means that Cytodyn generated $-1.16 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cytodyn Inc:

  • The MRQ is -116.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -119.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-116.1%TTM-119.5%+3.4%
TTM-119.5%YOY-230.6%+111.1%
TTM-119.5%5Y-103.9%-15.6%
5Y-103.9%10Y-96.0%-7.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-116.1%-13.3%-102.8%
TTM-119.5%-12.8%-106.7%
YOY-230.6%-11.6%-219.0%
5Y-103.9%-13.8%-90.1%
10Y-96.0%-15.6%-80.4%
1.1.3. Return on Equity

Shows how efficient Cytodyn is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cytodyn to the Biotechnology industry mean.
  • 0.0% Return on Equity means Cytodyn generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cytodyn Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-55.7%+55.7%
5Y-55.7%10Y-49.8%-5.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM--16.1%+16.1%
YOY--14.9%+14.9%
5Y-55.7%-19.3%-36.4%
10Y-49.8%-20.1%-29.7%

1.2. Operating Efficiency of Cytodyn Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cytodyn is operating .

  • Measures how much profit Cytodyn makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cytodyn to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cytodyn Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-518.5%+518.5%
TTM-5Y366.3%-366.3%
5Y366.3%10Y183.2%+183.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY-518.5%-288.4%-230.1%
5Y366.3%-486.2%+852.5%
10Y183.2%-628.4%+811.6%
1.2.2. Operating Ratio

Measures how efficient Cytodyn is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cytodyn Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY6.194-6.194
TTM-5Y-2.316+2.316
5Y-2.31610Y-1.158-1.158
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY6.1943.838+2.356
5Y-2.3165.679-7.995
10Y-1.1587.823-8.981

1.3. Liquidity of Cytodyn Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cytodyn is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.08 means the company has $0.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cytodyn Inc:

  • The MRQ is 0.077. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.083. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.077TTM0.083-0.006
TTM0.083YOY0.084-0.001
TTM0.0835Y0.445-0.362
5Y0.44510Y0.780-0.335
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0773.863-3.786
TTM0.0834.169-4.086
YOY0.0845.337-5.253
5Y0.4456.122-5.677
10Y0.7806.434-5.654
1.3.2. Quick Ratio

Measures if Cytodyn is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cytodyn to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cytodyn Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.046-0.046
TTM-5Y0.092-0.092
5Y0.09210Y0.446-0.353
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.504-3.504
TTM-3.991-3.991
YOY0.0465.371-5.325
5Y0.0926.088-5.996
10Y0.4466.395-5.949

1.4. Solvency of Cytodyn Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cytodyn assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cytodyn to Biotechnology industry mean.
  • A Debt to Asset Ratio of 12.62 means that Cytodyn assets are financed with 1,262.4% credit (debt) and the remaining percentage (100% - 1,262.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cytodyn Inc:

  • The MRQ is 12.624. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 11.780. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ12.624TTM11.780+0.845
TTM11.780YOY8.565+3.215
TTM11.7805Y4.801+6.979
5Y4.80110Y3.185+1.616
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.6240.339+12.285
TTM11.7800.337+11.443
YOY8.5650.271+8.294
5Y4.8010.368+4.433
10Y3.1850.388+2.797
1.4.2. Debt to Equity Ratio

Measures if Cytodyn is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cytodyn to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cytodyn Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.636-1.636
5Y1.63610Y1.147+0.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.392-0.392
TTM-0.403-0.403
YOY-0.335-0.335
5Y1.6360.427+1.209
10Y1.1470.461+0.686

2. Market Valuation of Cytodyn Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cytodyn generates.

  • Above 15 is considered overpriced but always compare Cytodyn to the Biotechnology industry mean.
  • A PE ratio of -5.42 means the investor is paying $-5.42 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cytodyn Inc:

  • The EOD is -3.042. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.417. Based on the earnings, the company is expensive. -2
  • The TTM is -4.434. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.042MRQ-5.417+2.375
MRQ-5.417TTM-4.434-0.983
TTM-4.434YOY-4.011-0.423
TTM-4.4345Y-8.835+4.402
5Y-8.83510Y-17.237+8.402
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.042-2.300-0.742
MRQ-5.417-2.656-2.761
TTM-4.434-2.718-1.716
YOY-4.011-4.145+0.134
5Y-8.835-6.258-2.577
10Y-17.237-6.315-10.922
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cytodyn Inc:

  • The EOD is -15.528. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -27.653. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -18.763. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.528MRQ-27.653+12.125
MRQ-27.653TTM-18.763-8.889
TTM-18.763YOY-14.487-4.276
TTM-18.7635Y-17.394-1.369
5Y-17.39410Y-16.753-0.641
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.528-2.974-12.554
MRQ-27.653-3.306-24.347
TTM-18.763-3.508-15.255
YOY-14.487-5.613-8.874
5Y-17.394-8.378-9.016
10Y-16.753-8.873-7.880
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cytodyn is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -2.16 means the investor is paying $-2.16 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cytodyn Inc:

  • The EOD is -1.215. Based on the equity, the company is expensive. -2
  • The MRQ is -2.163. Based on the equity, the company is expensive. -2
  • The TTM is -1.946. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.215MRQ-2.163+0.949
MRQ-2.163TTM-1.946-0.218
TTM-1.946YOY-3.725+1.779
TTM-1.9465Y-65.853+63.908
5Y-65.85310Y-44.639-21.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.2151.914-3.129
MRQ-2.1632.116-4.279
TTM-1.9462.097-4.043
YOY-3.7252.881-6.606
5Y-65.8533.550-69.403
10Y-44.6393.936-48.575
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Cytodyn Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.005-0.003-38%-0.021+323%-0.006+13%-0.003-37%
Book Value Per Share---0.120-0.116-4%-0.104-14%-0.051-58%-0.027-78%
Current Ratio--0.0770.083-8%0.084-9%0.445-83%0.780-90%
Debt To Asset Ratio--12.62411.780+7%8.565+47%4.801+163%3.185+296%
Debt To Equity Ratio----0%-0%1.636-100%1.147-100%
Dividend Per Share----0%-0%0.000-100%0.000-100%
Eps---0.012-0.013+9%-0.043+261%-0.031+159%-0.019+61%
Free Cash Flow Per Share---0.002-0.003+36%-0.007+197%-0.016+560%-0.013+448%
Free Cash Flow To Equity Per Share--0.001-0.001+159%0.000+108%0.000+111%0.001+37%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.925+8%
Intrinsic Value_10Y_max--0.786--------
Intrinsic Value_10Y_min--0.634--------
Intrinsic Value_1Y_max---0.030--------
Intrinsic Value_1Y_min---0.030--------
Intrinsic Value_3Y_max---0.008--------
Intrinsic Value_3Y_min---0.009--------
Intrinsic Value_5Y_max--0.115--------
Intrinsic Value_5Y_min--0.099--------
Market Cap145031438.336-78%258275164.160223507353.600+16%377479086.080-32%1146841065.472-77%956782829.046-73%
Net Profit Margin----0%-8.9130%3.148-100%1.574-100%
Operating Margin----0%-5.1850%3.663-100%1.832-100%
Operating Ratio----0%6.194-100%-2.3160%-1.1580%
Pb Ratio-1.215+44%-2.163-1.946-10%-3.725+72%-65.853+2944%-44.639+1963%
Pe Ratio-3.042+44%-5.417-4.434-18%-4.011-26%-8.835+63%-17.237+218%
Price Per Share0.146-78%0.2600.225+16%0.380-32%1.155-77%0.963-73%
Price To Free Cash Flow Ratio-15.528+44%-27.653-18.763-32%-14.487-48%-17.394-37%-16.753-39%
Price To Total Gains Ratio-29.000+44%-51.645-29.058-44%1505.237-103%329.065-116%523.330-110%
Quick Ratio----0%0.046-100%0.092-100%0.446-100%
Return On Assets---1.161-1.195+3%-2.306+99%-1.039-10%-0.960-17%
Return On Equity----0%-0%-0.5570%-0.4980%
Total Gains Per Share---0.005-0.003-38%-0.021+323%-0.006+12%-0.003-37%
Usd Book Value---119382000.000-115038250.000-4%-102922250.000-14%-50448692.050-58%-26713202.175-78%
Usd Book Value Change Per Share---0.005-0.003-38%-0.021+323%-0.006+13%-0.003-37%
Usd Book Value Per Share---0.120-0.116-4%-0.104-14%-0.051-58%-0.027-78%
Usd Dividend Per Share----0%-0%0.000-100%0.000-100%
Usd Eps---0.012-0.013+9%-0.043+261%-0.031+159%-0.019+61%
Usd Free Cash Flow---2335000.000-3186000.000+36%-6928000.000+197%-15411981.500+560%-10229660.250+338%
Usd Free Cash Flow Per Share---0.002-0.003+36%-0.007+197%-0.016+560%-0.013+448%
Usd Free Cash Flow To Equity Per Share--0.001-0.001+159%0.000+108%0.000+111%0.001+37%
Usd Market Cap145031438.336-78%258275164.160223507353.600+16%377479086.080-32%1146841065.472-77%956782829.046-73%
Usd Price Per Share0.146-78%0.2600.225+16%0.380-32%1.155-77%0.963-73%
Usd Profit---11920000.000-12922500.000+8%-43034250.000+261%-30883465.050+159%-19129176.825+60%
Usd Revenue----0%778000.000-100%-206050.0000%-103025.0000%
Usd Total Gains Per Share---0.005-0.003-38%-0.021+323%-0.006+12%-0.003-37%
 EOD+2 -6MRQTTM+15 -11YOY+17 -125Y+15 -1710Y+12 -21

3.2. Fundamental Score

Let's check the fundamental score of Cytodyn Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.042
Price to Book Ratio (EOD)Between0-1-1.215
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than10.077
Debt to Asset Ratio (MRQ)Less than112.624
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-1.161
Total1/10 (10.0%)

3.3. Technical Score

Let's check the technical score of Cytodyn Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.565
Ma 20Greater thanMa 500.156
Ma 50Greater thanMa 1000.170
Ma 100Greater thanMa 2000.185
OpenGreater thanClose0.146
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2024-02-29. Currency in USD. All numbers in thousands.

Summary
Total Assets10,270
Total Liabilities129,652
Total Stockholder Equity-119,382
 As reported
Total Liabilities 129,652
Total Stockholder Equity+ -119,382
Total Assets = 10,270

Assets

Total Assets10,270
Total Current Assets9,910
Long-term Assets360
Total Current Assets
Cash And Cash Equivalents 1,404
Total Current Assets  (as reported)9,910
Total Current Assets  (calculated)1,404
+/- 8,506
Long-term Assets
Long-term Assets Other 360
Long-term Assets  (as reported)360
Long-term Assets  (calculated)360
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities129,476
Long-term Liabilities176
Total Stockholder Equity-119,382
Total Current Liabilities
Short Long Term Debt 30,169
Accounts payable 62,078
Other Current Liabilities 6,172
Total Current Liabilities  (as reported)129,476
Total Current Liabilities  (calculated)98,419
+/- 31,057
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt318
Long-term Liabilities  (as reported)176
Long-term Liabilities  (calculated)318
+/- 142
Total Stockholder Equity
Total Stockholder Equity (as reported)-119,382
Total Stockholder Equity (calculated)0
+/- 119,382
Other
Capital Stock990
Common Stock Shares Outstanding 989,925
Net Debt 28,765
Net Invested Capital -89,213
Net Working Capital -119,566



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-02-292023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-05-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-312010-05-312010-02-282009-11-302009-08-31
> Total Assets 
142
180
1,145
748
465
2,095
3,375
1,995
1,470
981
2,556
1,071
842
5,563
4,480
4,158
4,446
13,643
11,016
8,427
5,586
5,664
4,675
4,679
6,139
6,561
14,586
13,786
9,293
15,674
14,758
8,055
6,128
6,491
8,285
4,899
9,031
20,391
20,428
20,874
18,387
17,917
38,818
50,514
93,362
143,762
113,654
132,080
104,970
103,699
94,079
29,185
28,394
7,074
14,642
11,292
12,411
9,240
10,270
10,2709,24012,41111,29214,6427,07428,39429,18594,079103,699104,970132,080113,654143,76293,36250,51438,81817,91718,38720,87420,42820,3919,0314,8998,2856,4916,1288,05514,75815,6749,29313,78614,5866,5616,1394,6794,6755,6645,5868,42711,01613,6434,4464,1584,4805,5638421,0712,5569811,4701,9953,3752,0954657481,145180142
   > Total Current Assets 
0
0
0
0
0
0
0
0
1,421
0
0
0
0
2,023
941
840
1,014
10,490
7,951
5,443
2,675
2,844
1,945
2,038
3,587
4,100
12,215
11,494
7,090
13,563
12,734
6,121
4,282
4,735
6,617
3,321
7,540
3,928
4,467
5,369
3,200
3,245
24,602
36,827
79,876
130,794
110,855
129,581
102,786
101,810
92,349
10,515
9,857
6,551
14,110
10,805
11,968
8,840
9,910
9,9108,84011,96810,80514,1106,5519,85710,51592,349101,810102,786129,581110,855130,79479,87636,82724,6023,2453,2005,3694,4673,9287,5403,3216,6174,7354,2826,12112,73413,5637,09011,49412,2154,1003,5872,0381,9452,8442,6755,4437,95110,4901,0148409412,02300001,42100000000
       Cash And Cash Equivalents 
94
126
987
700
411
98
477
3
493
130
1,780
285
66
1,430
412
604
676
10,133
7,395
4,886
2,296
2,377
1,670
1,050
2,832
3,252
10,202
9,642
4,444
8,811
7,796
1,776
946
1,297
4,947
1,231
4,749
772
1,594
2,613
1,796
409
7,057
14,282
18,200
29,407
14,291
33,943
6,542
8,875
2,363
4,231
4,676
2,603
11,110
2,541
2,034
147
1,404
1,4041472,0342,54111,1102,6034,6764,2312,3638,8756,54233,94314,29129,40718,20014,2827,0574091,7962,6131,5947724,7491,2314,9471,2979461,7767,7968,8114,4449,64210,2023,2522,8321,0501,6702,3772,2964,8867,39510,1336766044121,430662851,78013049334779841170098712694
       Short-term Investments 
0
0
0
0
0
0
267
1,036
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000001,036267000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
91
5
5
2
0
0
0
0
0
41
225
0
0
0
0
0
0
0
0
0
000000000225410000025591000000000000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,896
19,147
58,474
99,071
93,537
93,479
91,558
88,557
82,668
17,929
0
0
0
0
0
0
0
000000017,92982,66888,55791,55893,47993,53799,07158,47419,14715,896000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
49
0
0
0
0
3,540
3,539
3,317
200
3,153
3,065
2,984
2,911
2,820
2,730
2,641
2,551
2,461
2,371
2,292
2,203
2,110
2,024
1,935
1,845
1,756
1,667
1,578
1,492
16,463
9
15,505
15,187
14,672
14,216
13,687
13,486
12,968
2,799
2,499
2,184
1,889
1,730
741
18,537
523
532
487
443
400
360
36040044348753252318,5377411,7301,8892,1842,4992,79912,96813,48613,68714,21614,67215,18715,505916,4631,4921,5781,6671,7561,8451,9352,0242,1102,2032,2922,3712,4612,5512,6412,7302,8202,9112,9843,0653,1532003,3173,5393,54000004900000000
       Property Plant Equipment 
4
3
4
4
6
7
6
5
1
1
1
1
1
1
0
0
2
11
10
17
31
28
25
24
22
19
16
25
23
18
19
17
16
14
12
11
12
10
9
29
240
222
263
231
107
115
124
134
129
119
117
73
17,929
468
434
400
0
0
0
00040043446817,9297311711912913412411510723126322224029910121112141617191823251619222425283117101120011111156764434
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
3,500
39
3,317
3,230
3,142
3,055
2,967
2,880
2,792
2,705
2,617
2,530
2,442
2,355
2,267
2,180
2,092
2,005
1,917
1,830
1,742
1,655
1,567
1,480
16,453
15,951
15,475
14,947
14,450
13,953
13,456
12,959
12,462
1,915
1,653
1,390
1,153
1,043
132
0
0
0
0
0
0
0
00000001321,0431,1531,3901,6531,91512,46212,95913,45613,95314,45014,94715,47515,95116,4531,4801,5671,6551,7421,8301,9172,0052,0922,1802,2672,3552,4422,5302,6172,7052,7922,8802,9673,0553,1423,2303,317393,5000000000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
48
0
0
0
0
39
3,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15,960
15,505
15,187
14,672
14,216
176
420
391
760
712
665
617
570
536
608
523
532
487
443
400
360
36040044348753252360853657061766571276039142017614,21614,67215,18715,50515,960000000000000000000000003,5003900004800000000
> Total Liabilities 
784
873
811
5,788
5,581
5,805
7,843
7,003
7,400
7,336
5,012
5,044
5,660
5,345
4,607
4,382
4,867
4,152
4,251
4,505
4,906
7,352
8,373
15,372
12,853
9,270
3,379
3,581
3,039
10,297
9,341
9,159
14,485
19,281
15,877
18,057
28,829
28,455
26,677
29,788
25,181
31,549
43,201
52,995
90,594
150,296
129,449
153,098
130,163
116,395
116,539
123,583
122,706
123,043
121,652
120,793
129,300
123,621
129,652
129,652123,621129,300120,793121,652123,043122,706123,583116,539116,395130,163153,098129,449150,29690,59452,99543,20131,54925,18129,78826,67728,45528,82918,05715,87719,28114,4859,1599,34110,2973,0393,5813,3799,27012,85315,3728,3737,3524,9064,5054,2514,1524,8674,3824,6075,3455,6605,0445,0127,3367,4007,0037,8435,8055,5815,788811873784
   > Total Current Liabilities 
396
636
575
5,551
5,574
5,798
7,836
6,995
7,391
6,662
5,003
5,035
5,651
5,078
3,930
3,229
3,523
2,517
2,268
2,166
2,211
4,555
6,589
10,725
12,853
9,270
3,379
3,581
3,039
6,341
5,358
6,144
11,108
16,734
12,588
16,733
24,139
23,983
22,259
26,926
23,067
29,702
41,004
44,501
76,424
115,730
128,861
152,546
129,644
115,909
116,086
123,161
122,319
122,690
121,334
119,796
129,053
123,410
129,476
129,476123,410129,053119,796121,334122,690122,319123,161116,086115,909129,644152,546128,861115,73076,42444,50141,00429,70223,06726,92622,25923,98324,13916,73312,58816,73411,1086,1445,3586,3413,0393,5813,3799,27012,85310,7256,5894,5552,2112,1662,2682,5173,5233,2293,9305,0785,6515,0355,0036,6627,3916,9957,8365,7985,5745,551575636396
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
328
670
294
248
0
0
2,119
2,619
1,634
2,991
0
0
0
0
0
0
1,059
4,495
5,392
0
0
2,455
4,200
2,272
7,786
8,586
7,728
3,916
0
0
0
37,976
62,747
51,333
43,947
35,647
36,241
36,833
36,931
36,013
0
0
0
0
000036,01336,93136,83336,24135,64743,94751,33362,74737,9760003,9167,7288,5867,7862,2724,2002,455005,3924,4951,0590000002,9911,6342,6192,11900248294670328000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,059
4,495
5,392
0
0
2,455
4,200
6,472
7,786
8,586
7,728
3,916
6,744
18,124
50,676
37,976
62,747
51,333
43,947
35,647
36,241
36,833
36,931
36,013
34,417
33,100
32,914
30,169
30,16932,91433,10034,41736,01336,93136,83336,24135,64743,94751,33362,74737,97650,67618,1246,7443,9167,7288,5867,7866,4724,2002,455005,3924,4951,0590000000000000000000000000000000
       Accounts payable 
266
306
253
179
178
254
501
933
1,508
1,496
756
831
1,158
1,982
1,586
2,364
2,317
1,686
1,642
1,788
1,833
2,058
2,526
5,946
6,800
6,356
3,319
3,338
2,981
6,283
5,300
4,448
5,937
11,342
12,588
16,733
21,684
19,783
15,787
16,239
12,048
18,654
34,179
29,479
59,577
64,943
92,902
73,151
74,249
68,559
74,520
81,902
84,833
84,608
81,958
62,725
62,773
62,328
62,078
62,07862,32862,77362,72581,95884,60884,83381,90274,52068,55974,24973,15192,90264,94359,57729,47934,17918,65412,04816,23915,78719,78321,68416,73312,58811,3425,9374,4485,3006,2832,9813,3383,3196,3566,8005,9462,5262,0581,8331,7881,6421,6862,3172,3641,5861,9821,1588317561,4961,508933501254178179253306266
       Other Current Liabilities 
62
112
115
5,218
5,242
5,395
7,186
5,913
5,892
5,017
4,172
4,130
4,419
3,097
2,344
537
537
537
378
378
378
378
353
3,145
3,062
2,914
60
243
58
58
58
637
676
1,625
933
891
972
930
4,200
854
148
1,089
565
991
18,247
50,787
183
19,248
7,062
6,803
9,554
8,995
5,014
5,722
8,298
10,365
6,953
33
6,172
6,172336,95310,3658,2985,7225,0148,9959,5546,8037,06219,24818350,78718,2479915651,0891488544,2009309728919331,625676637585858243602,9143,0623,1453533783783783785375375372,3443,0974,4194,1304,1725,0175,8925,9137,1865,3955,2425,21811511262
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
266
677
1,153
1,344
1,635
1,983
2,339
2,695
1,662
1,784
4,647
0
0
0
0
0
3,956
3,982
3,015
3,377
2,548
3,289
1,324
4,690
4,472
4,418
2,862
2,115
1,847
2,197
8,494
14,170
34,566
588
552
519
486
453
422
387
353
318
997
247
211
176
17621124799731835338742245348651955258834,56614,1708,4942,1971,8472,1152,8624,4184,4724,6901,3243,2892,5483,3773,0153,9823,956000004,6471,7841,6622,6952,3391,9831,6351,3441,1536772660000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
266
677
1,153
1,344
1,635
1,983
2,339
2,695
89
1,226
2,638
0
0
0
0
0
0
0
0
0
0
0
0
2,618
1,397
0
0
0
0
0
8,431
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000008,431000001,3972,6180000000000002,6381,226892,6952,3391,9831,6351,3441,1536772660000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-328
-670
-294
-248
0
0
-2,119
-2,619
-1,634
-2,991
0
0
0
0
0
0
-1,059
-4,495
-5,392
0
0
-2,455
-4,200
-2,272
-7,786
-8,377
-7,542
-3,709
178
424
397
-37,205
-62,020
-50,652
-43,312
-35,058
-35,685
-36,446
-36,578
-35,695
283
387
353
318
318353387283-35,695-36,578-36,446-35,685-35,058-43,312-50,652-62,020-37,205397424178-3,709-7,542-8,377-7,786-2,272-4,200-2,45500-5,392-4,495-1,059000000-2,991-1,634-2,619-2,11900-248-294-670-328000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,418
2,862
2,115
1,847
2,197
63
14,170
34,566
588
552
519
486
453
422
387
353
318
0
0
0
0
000031835338742245348651955258834,56614,170632,1971,8472,1152,8624,41800000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,573
557
2,009
0
0
0
0
0
3,956
3,982
3,015
3,377
2,548
3,289
1,324
2,071
3,075
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000003,0752,0711,3243,2892,5483,3773,0153,9823,956000002,0095571,573000000000000000000000
> Total Stockholder Equity
0
0
334
0
0
0
0
0
-5,930
0
0
0
0
218
-127
-224
-420
9,491
6,765
3,922
680
-1,689
-3,699
-10,693
-6,714
-2,709
11,206
10,205
6,253
5,377
5,417
-1,103
-8,358
-12,791
-7,593
-13,158
-19,797
-8,064
-6,249
-8,914
-6,795
-13,632
-4,383
-2,480
2,768
-6,534
-15,795
-21,018
-25,193
-12,696
-22,460
-94,398
-94,312
-115,969
-107,010
-109,501
-116,889
-114,381
-119,382
-119,382-114,381-116,889-109,501-107,010-115,969-94,312-94,398-22,460-12,696-25,193-21,018-15,795-6,5342,768-2,480-4,383-13,632-6,795-8,914-6,249-8,064-19,797-13,158-7,593-12,791-8,358-1,1035,4175,3776,25310,20511,206-2,709-6,714-10,693-3,699-1,6896803,9226,7659,491-420-224-1272180000-5,9300000033400
   Retained Earnings -874,744-862,824-853,261-841,690-823,054-809,352-782,857-766,131-636,078-603,353-542,653-511,294-465,983-421,587-386,206-354,711-296,683-260,649-245,638-229,363-214,432-201,858-187,553-173,139-163,516-145,566-134,618-122,990-116,160-108,048-102,580-97,226-90,729-85,682-80,417-71,522-57,519-54,798-49,814-46,434-41,836-38,562-34,974-32,401-29,915-27,5560000-16,52500000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
6,119
0
0
0
0
16,022
16,754
17,524
18,950
19,403
19,701
20,100
20,238
20,900
21,323
24,763
73,623
82,882
101,817
107,308
108,709
113,286
121,427
121,737
126,107
132,610
155,714
159,765
167,522
193,504
207,879
220,120
238,460
246,618
291,829
351,711
388,404
414,463
449,579
489,650
516,816
589,971
612,905
671,013
687,732
692,558
715,207
0
0
0
0
0000715,207692,558687,732671,013612,905589,971516,816489,650449,579414,463388,404351,711291,829246,618238,460220,120207,879193,504167,522159,765155,714132,610126,107121,737121,427113,286108,709107,308101,81782,88273,62324,76321,32320,90020,23820,10019,70119,40318,95017,52416,75416,02200006,11900000000
   Treasury Stock0000000000000000000000000000000000000000-100-100-100-100-100-100-100-100-100-100-100-100-100-100-100-1000-1590



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-05-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-20,633
Gross Profit-20,633-20,633
 
Operating Income (+$)
Gross Profit-20,633
Operating Expense-40,576
Operating Income-40,576-61,209
 
Operating Expense (+$)
Research Development2,632
Selling General Administrative17,136
Selling And Marketing Expenses0
Operating Expense40,57619,768
 
Net Interest Income (+$)
Interest Income0
Interest Expense-6,750
Other Finance Cost-23,748
Net Interest Income-30,498
 
Pretax Income (+$)
Operating Income-40,576
Net Interest Income-30,498
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-79,824-31,826
EBIT - interestExpense = -47,326
-79,824
-73,074
Interest Expense6,750
Earnings Before Interest and Taxes (EBIT)-40,576-73,074
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-79,824
Tax Provision-0
Net Income From Continuing Ops-79,824-79,824
Net Income-79,824
Net Income Applicable To Common Shares-86,736
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-8,75030,498
 

Technical Analysis of Cytodyn
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cytodyn. The general trend of Cytodyn is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cytodyn's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cytodyn Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.16 < 0.16 < 0.16.

The bearish price targets are: 0.13 > 0.13.

Tweet this
Cytodyn Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cytodyn Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cytodyn Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cytodyn Inc. The current macd is -0.0060753.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytodyn price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cytodyn. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cytodyn price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Cytodyn Inc Daily Moving Average Convergence/Divergence (MACD) ChartCytodyn Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cytodyn Inc. The current adx is 23.64.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Cytodyn shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Cytodyn Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cytodyn Inc. The current sar is 0.1574.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Cytodyn Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cytodyn Inc. The current rsi is 40.57. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Cytodyn Inc Daily Relative Strength Index (RSI) ChartCytodyn Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cytodyn Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Cytodyn price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Cytodyn Inc Daily Stochastic Oscillator ChartCytodyn Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cytodyn Inc. The current cci is -94.04324765.

Cytodyn Inc Daily Commodity Channel Index (CCI) ChartCytodyn Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cytodyn Inc. The current cmo is -24.54084579.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Cytodyn Inc Daily Chande Momentum Oscillator (CMO) ChartCytodyn Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cytodyn Inc. The current willr is -60.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cytodyn is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cytodyn Inc Daily Williams %R ChartCytodyn Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cytodyn Inc.

Cytodyn Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cytodyn Inc. The current atr is 0.01183946.

Cytodyn Inc Daily Average True Range (ATR) ChartCytodyn Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cytodyn Inc. The current obv is -10,567,787.

Cytodyn Inc Daily On-Balance Volume (OBV) ChartCytodyn Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cytodyn Inc. The current mfi is 26.27.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cytodyn Inc Daily Money Flow Index (MFI) ChartCytodyn Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cytodyn Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Cytodyn Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cytodyn Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5040.565
Ma 20Greater thanMa 500.156
Ma 50Greater thanMa 1000.170
Ma 100Greater thanMa 2000.185
OpenGreater thanClose0.146
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cytodyn with someone you think should read this too:
  • Are you bullish or bearish on Cytodyn? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cytodyn? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cytodyn Inc

I send you an email if I find something interesting about Cytodyn Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Cytodyn Inc.

Receive notifications about Cytodyn Inc in your mailbox!